StemCell Therapy

A study from the National Institutes of Health confirms that neurofilament light chain as a blood biomarker can detect brain injury and predict recovery in multiple groups, including professional hockey players with acute or chronic concussions and clinic-based patients with mild, moderate, or severe traumatic brain injury. The research was conducted by scientists at the NIH Clinical Center, Bethesda, Maryland, and published in the July 8, 2020, online issue of Neurology.

After a traumatic brain injury, neurofilament light chain breaks away from neurons in the brain and collects in the cerebrospinal fluid (CSF). The scientists confirmed that neurofilament light chain also collects in the blood in levels that correlate closely with the levels in the CSF. They demonstrated that neurofilament light chain in the blood can detect brain injury and predict recovery across all stages of traumatic brain injury.

Currently, there are no validated blood-based biomarkers to provide an objective diagnosis of mild traumatic brain injury or to predict recovery, said Leighton Chan, M.D., M.P.H., chief of the Rehabilitation Medicine Department at the NIH Clinical Center. Our study reinforces the need and a way forward for a non-invasive test of neurofilament light chain to aid in the diagnosis of patients and athletes whose brain injuries are often unrecognized, undiagnosed or underreported."

The study examined multiple groups including professional hockey players in Sweden with sports-related concussions, hockey players without concussions, hockey players with persistent post-concussion symptoms, non-athlete controls, and clinic-based patients at the NIH Clinical Center who were healthy or with acute, subacute, and chronic mild traumatic brain injuries. The study showed that neurofilament light chain in the blood:

- Correlated closely with CSF neurofilament light chain in hockey players with concussions and non-athlete healthy controls, suggesting that blood neurofilament light chain could be used instead of CSF neurofilament light chain.

- Demonstrated strong diagnostic ability for sports-related concussions, where it could identify hockey players with concussions from hockey players without concussions and could identify clinic-based patients with mild, moderate, and severe traumatic brain injuries from each other and controls. This is significant as there is an unmet need for an easy and accessible blood biomarker to determine at the time of injury or in the chronic phase if a person has a concussion or signs of a traumatic brain injury.

- Could distinguish with high accuracy hockey players who could return to play after 10 days from those who developed persistent post-concussion symptoms and eventually retired from the game. In the clinic-based cohort, patients with worse functional outcomes had higher blood neurofilament light chain levels. This is significant as there is an unmet need for a blood biomarker that can help clinicians to determine when athletes can safely return to play or when patients can return to work or resume daily activities.

In the clinic-based patients, the levels of blood neurofilament light chain at five years after a single mild, moderate, or severe traumatic brain injury were significantly increased compared to healthy controls. This suggests that even a single mild traumatic brain injury (without visible signs of structural damage on a standard clinical MRI) may cause long-term brain injury, and serum neurofilament light could be a sensitive biomarker to detect even that far out from initial injury.

This study is the first to do a detailed assessment of serum neurofilament light chain and advanced brain imaging in multiple cohorts, brain injury severities, and time points after injury, said the studys lead author, Pashtun Shahim, M.D., Ph.D., NIH Clinical Center. Our results suggest that serum neurofilament light chain may provide a valuable compliment to imaging by detecting underlying neuronal damage which may be responsible for the long-term symptoms experienced by a significant number of athletes with acute concussions, and patients with more severe brain injuries.

The study was funded by the Intramural Research Program at NIH, the Department of Defense Center for Neuroscience and Regenerative Medicine at the Uniformed Services University, and the Swedish Research Council.

Traumatic brain injury is a major leading cause of death and disability in the United States with more than 2.87 million emergency department visits, hospitalizations and deaths annually. While majority of all traumatic brain injuries are classified as mild (also known as a concussion), it remains difficult to diagnose this condition. There are a wide range of variable behavioral and observational tests to help determine a patients injuries but most of these tests rely on the patient to self-report signs and symptoms. Also, imaging has limitations with detecting micro-structural injuries in the brain.

Reference:Shahim, P., Politis, A., Merwe, A. V., Moore, B., Chou, Y., Pham, D. L., . . . Chan, L. (2020). Neurofilament Light as a Biomarker in Traumatic Brain Injury. Neurology. doi:10.1212/wnl.0000000000009983

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continue reading here:
Blood-based Biomarker Can Detect and Predict Severity of Traumatic Brain Injury - Technology Networks

Californians will see a lengthy list of initiatives and referendums on the November ballot.

Secretary of State Alex Padilla has assigned proposition numbers to 12 measures that have qualified for the ballot, from funding for stem cell research to a repeal of the states ban on affirmative action and an expansion of consumer privacy laws. Each must be approved by a simple majority to become law.

Proposition 14: Stem cell research. Would re-fund the California Institute for Regenerative Medicine, the states stem cell agency, by allowing it to issue $5.5 billion in bonds for research, training and facilities construction.

Proposition 15: Limits on property taxes. Would rewrite Proposition 13, the landmark 1978 measure that limits property tax increases and allows residential and commercial property to be reassessed only when it is sold.

Prop. 15 would boost property taxes on large commercial and industrial property by allowing it to be reappraised more frequently. The added money would go to school districts and local governments. Prop. 13 rules for residential property would be unchanged.

Proposition 16: Affirmative action. A constitutional amendment, proposed by state legislators, that would reverse Californias voter-approved 1996 ban on affirmative action. It would repeal Proposition 209, which prohibits public universities, schools and government agencies from using race or sex in their admissions criteria, hiring and contract decisions.

Proposition 17: Parolee voting. A constitutional amendment, proposed by state legislators, that would restore the voting rights of all people on parole if theyve completed their state or federal prison terms.

Proposition 18: Voting age. A constitutional amendment, proposed by state legislators, that would allow 17-year-olds to vote in primary elections if they would turn 18 before the general election.

Proposition 19: Property tax transfers. A constitutional amendment, proposed by state legislators, that would allow people age 55 and older, and victims of wildfires and other disasters, to keep lower property tax rates when they move to new homes.

Proposition 20: Criminal justice. Would make changes to the criminal justice system by revising two earlier initiatives, Proposition 47 and Proposition 57. The new measure would expand the list of violent crimes for which there is no early release, adding sex trafficking of a child and felony domestic violence. It would also require DNA collection for those convicted of several types of misdemeanors.

Proposition 21: Rent control. Would reverse a ban on local rent control laws. It would repeal the Costa-Hawkins Rental Housing Act, which prohibits cities from passing rent control ordinances for housing built since 1995. Voters overwhelmingly rejected a similar measure in 2018.

An earlier version of this story erroneously stated that two additional measures could qualify for the November ballot. The window for qualifying has closed.

Proposition 22: Gig worker classification. Would exempt app-based drivers, including those working for Uber, Lyft and DoorDash, from a state law that classifies gig workers as employees. The companies want to undo part of AB5, Californias gig-worker law, which aims to classify their drivers as employees and make them eligible for benefits. Under the ballot measure, the companies could keep drivers as independent contractors while granting them some benefits and earnings guarantees.

Proposition 23: Kidney dialysis clinics. Would increase state regulation of kidney dialysis clinics. Among the proposed requirements: Clinics would be prohibited from discriminating against patients based on their source of payment.

Proposition 24: Consumer data privacy. Would expand Californias consumer privacy law, passed in 2018. The measure would triple penalties for companies that break laws regarding the collection and sale of childrens private information. It would also create a state agency to enforce consumer privacy protections.

Proposition 25: Cash bail. Would overturn a 2018 law that eliminates cash bail as a requirement to release people from jail before trial.

Dustin Gardiner is a San Francisco Chronicle staff writer. Email: dustin.gardiner@sfchronicle.com Twitter: @dustingardiner

See original here:
California voters: Here are the 12 measures on the November ballot - San Francisco Chronicle

Newswise The key components of electrical connections between light receptors in the eye and the impact of these connections on the early steps of visual signal processing have been identified for the first time, according to research published today in Science Advances by The University of Texas Health Science Center at Houston (UTHealth).

To understand fully how the light receptors, called photoreceptors, impact the early stages of the process of vision, researchers have traditionally focused their attention on how two key sensory cells rods and cones convert elementary particles of light into electrical signals and how these signals are relayed to the brain through devoted circuits. Rods are used for night vision and cones are used for daytime and color vision. While it has been known for some time that electrical signals can spread between photoreceptors through cell connectors called gap junctions, the nature and function have remained poorly understood.

This research will lead to a better understanding of how the retina processes signals from the rods and the cones in the eyes, in particular under ambient lighting conditions when both photoreceptor types are active, such as at dawn and dusk. This knowledge is currently missing and may have to be taken into consideration when designing photoreceptor or retinal implants to restore vision, said Christophe P. Ribelayga, PhD, co-lead author of the study and associate professor and Bernice Weingarten Chair in the Ruiz Department of Ophthalmology & Visual Science at McGovern Medical School at UTHealth.

Co-lead author Steve Massey, PhD, is professor, Elizabeth Morford Chair, and research director in the Ruiz Department of Ophthalmology & Visual Science at McGovern Medical School at UTHealth.

The coupling or communication between rods and cones in the retina is critical for understanding how the visual signaling process works.

What the researchers discovered, to their surprise, is that rods do not directly communicate with other rods and cones seldom communicate directly with other cones. Instead, the majority of signaling happens through communication between rods and cones. Researchers identified a specific protein called connexin36 (Cx36) as the main component of rod/cone gap junctions.

We noted that every single rod has electrical access to a cone and that cone/cone gap junctions are very rare, Massey said. We estimated that more than 95% of all gap junctions between photoreceptors are rod/cone gap junctions; they have the largest volume and the largest conductance. So, rod/cone gap junctions dominate the network of photoreceptors both in size and number.

To help researchers better understand how the photoreceptor network is organized, they developed genetic mouse strains for the work that were bred to eliminate gap junctions in either rods or cones.

Our study has important implications, said Ribelayga. Our data position rod/cone gap junctions as the keystone of the photoreceptor network. The rod/cone gap junction is the entry of a rod pathway through which signals of rod origin can travel across the retina. We have thus generated mice that are essentially deficient for the entry of this pathway. In future experiments, we will use these animals to determine the functional importance of the rod/cone pathway in the retinal processing of rod signals and for vision.

In 2018, researchers in the Ruiz Department of Ophthalmology & Visual Science received more than $4 million in grants from the National Institutes of Healths National Eye Institute to study photoreceptor development, function, and electrical interactions. Ribelayga and Massey led the effort to lay out the architecture of the network of electrically coupled receptors, a critical step toward a better understanding of how photoreceptors encode light signals and how the retina processes these signals.

Additional UTHealth authors include Nange Jin, PhD; Zhijing Zhang, PhD; Joyce Keung, PhD; Munenori Ishibashi, PhD; Lian-Ming Tian; Iris Fahrenfort, PhD; Takae Kiyama, PhD; Chai-An Mao, PhD; David W. Marshak, PhD; Jiaqian Wu, PhD; Haichao Wei, PhD; and Yanan You, PhD. Marshak is with McGovern Medical Schools Department of Neurobiology and Anatomy; and Wu, Wei, and You are with the UTHealth Center for Stem Cell and Regenerative Medicine at the Brown Foundation Institute of Molecular Medicine.

Other authors include Sean B. Youn with Rice University; Eduardo Solessio, PhD; and Yumiko Umino, PhD, with the Center for Vision Research and SUNY Eye Institute at SUNY Upstate Medical University; and Friso Postma, PhD; and David L. Paul, PhD, with Harvard University.

See the original post:
Researchers uncover a critical early step of the visual process - Newswise

Latest released the research study on Global Sports Medicine Products Market, offers a detailed overview of the factors influencing the global business scope. Sports Medicine Products Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Sports Medicine Products The study covers emerging players data, including: competitive landscape, sales, revenue and global market share of top manufacturers are Arthrex, (United States), Smith & Nephew (United Kingdom), DePuy Synthes (United States), Stryker (United States), CONMED (United States), Zimmer Biomet (United States), Breg (United States), DJO Global (United States), Mueller Sports (United States), Wright Medical Group (United States), Medtronic (Ireland), RTI Surgical (United States) and Performance Health International (United States)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/21077-global-sports-medicine-products-market

Sports Medicine is refer as the field of medicine which involves preventing, diagnosing and treating the injuries related to sports or exercise. Not only it manages injuries but sports medicine also uses exercise intervention which prevent and manage chronic diseases like hypertension, diabetes, obesity and others. Sports medicine are common for other injuries also. The market of the sports injuries is growing tremendously due to rising sports activity

The Global Sports Medicine Products Market segments and Market Data Break Down are illuminated below:

by Type (Body reconstruction products, Body support & recovery products, Medical accessories), Application (Shoulder injuries, Foot and ankle injuries, Elbow and wrist injuries, Back and spine injuries, Hip and groin injuries, Knee injuries, Other injuries), Procedure (Tendinosis, Tendon to bone, Cartilage repair), End User (Hospitals & Emergency care, Trauma centers, Ambulatory care, Others)

Analyst at AMA have conducted special survey and have connected with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to fight the situation. A special chapter in the study presents Impact Analysis of COVID-19 on Sports Medicine Products Market along with tables and graphs related to various country and segments showcasing impact on growth trends.

Market Trend

Arrival of international players for marketing of the product and Growing developments of regenerative medicine, allografts, and therapy of stem cell to treat broken bones

Market Drivers

Growing incidences in sports related injuries and increased development in the regenerative medicine field and High incidence like fractures and ligament tears in sports is also driving the market related to devices of fracture and ligament repair

Opportunities

Growing initiatives in promoting sports medicine, and collaborations of research for sports medicine and Continuous influx of treatment modalities and new products

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/21077-global-sports-medicine-products-market

Strategic Points Covered in Table of Content of Global Sports Medicine Products Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Sports Medicine Products market

Chapter 2: Exclusive Summary the basic information of the Sports Medicine Products Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Sports Medicine Products

Chapter 4: Presenting the Sports Medicine Products Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2014-2019

Chapter 6: Evaluating the leading manufacturers of the Sports Medicine Products market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2025).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Sports Medicine Products Market is a valuable source of guidance for individuals and companies in decision framework.

Data Sources & MethodologyThe primary sources involves the industry experts from the Global Sports Medicine Products Market including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Companys Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.

For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/21077-global-sports-medicine-products-market

What benefits does AMA research study is going to provide?

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enables clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]Connect with us athttps://www.linkedin.com/company/advance-market-analyticshttps://www.facebook.com/AMA-Research-Media-LLP-344722399585916https://twitter.com/amareport

More:
Sports Medicine Products Market: In-Depth Market Research and Trends Analysis till 2025 - Cole of Duty

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Get Brochure of the Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=132

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Request For Covid19 Impact Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=132

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

This review is based on the findings of a TMR report, titled, Stem Cells Market (Product Adult Stem Cell, Human Embryonic Stem Cell, and Induced Pluripotent Stem; Sources Autologous and Allogeneic; Application Regenerative Medicine and Drug Discovery and Development; End Users Therapeutic Companies, Cell and Tissues Banks, Tools and Reagent Companies, and Service Companies) Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 20172025.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

The Stem Cells Market is segmented as below:

Global Stem Cells Market, by Product Type

Global Stem Cells Market, by Source

Global Stem Cells Market, by Application

Global Stem Cells Market, by End Users

Global Stem Cells Market, by Geography

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.co.uk/news-releases/increasing-awareness-about-post-operative-care-and-changing-dynamics-of-healthcare-industry-to-present-lucrative-growth-opportunities-for-adhesion-barriers-market-finds-tmr-889098039.html

2.https://www.biospace.com/article/microbiology-culture-market-soaring-demand-for-microbiology-culture-from-food-and-healthcare-industries-to-drive-global-market/

Go here to read the rest:
COVID-19 Impact and Recovery Analysis Stem Cells Market 2017 2025 - Cole of Duty

The 2020 award celebrates outstanding research in rare diseases

NEW YORK & OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK) and the New York Academy of Sciences announced today the Winners of the third annual Innovators in Science Award for their excellence in and commitment to innovative science that has significantly advanced the field of rare disease research. Each Winner receives a prize of US $200,000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005039/en/

The 2020 Winner of the Senior Scientist Award is Adrian R. Krainer, Ph.D., St. Giles Foundation Professor at Cold Spring Harbor Laboratory. Prof. Krainer is recognized for his outstanding research on the mechanisms and control of RNA splicing, a step in the normal process by which genetic information in DNA is converted into proteins. Prof. Krainer studies splicing defects in patients with spinal muscular atrophy (SMA), a devastating, inherited pediatric neuromuscular disorder caused by loss of motor neurons, resulting in progressive muscle atrophy and eventually, death. Prof. Krainers work culminated notably in the development of the first drug to be approved by global regulatory bodies that can delay and even prevent the onset of an inherited neurodegenerative disorder.

Collectively, rare diseases affect millions of families worldwide, who urgently need and deserve our help. Im extremely honored to receive this recognition for research that my lab and our collaborators carried out to develop the first approved medicine for SMA, said Prof. Krainer. As basic researchers, we are driven by curiosity and get to experience the thrill of discovery; but when the fruits of our research can actually improve patients lives, everything else pales in comparison.

The 2020 Winner of the Early-Career Scientist Award is Jeong Ho Lee, M.D., Ph.D, Associate Professor, Korea Advanced Institute of Science and Technology (KAIST). Prof. Lee is recognized for his research investigating genetic mutations in stem cells in the brain that result in rare developmental brain disorders. He was the first to identify the causes of intractable epilepsies and has identified the genes responsible for several developmental brain disorders, including focal cortical dysplasias, Joubert syndromea disorder characterized by an underdevelopment of the brainstemand hemimegalencephaly, which is the abnormal enlargement of one side of the brain. Prof. Lee also is the Director of the National Creative Research Initiative Center for Brain Somatic Mutations, and Co-founder and Chief Technology Officer of SoVarGen, a biopharmaceutical company aiming to discover novel therapeutics and diagnosis for intractable central nervous system (CNS) diseases caused by low-level somatic mutation.

It is a great honor to be recognized by a jury of such globally respected scientists whom I greatly admire, said Prof. Lee. More importantly, this award validates research into brain somatic mutations as an important area of exploration to help patients suffering from devastating and untreatable neurological disorders.

The 2020 Winners will be honored at the virtual Innovators in Science Award Ceremony and Symposium in October 2020. This event provides an opportunity to engage with leading researchers, clinicians and prominent industry stakeholders from around the world about the latest breakthroughs in the scientific understanding and clinical treatment of genetic, nervous system, metabolic, autoimmune and cardiovascular rare diseases.

At Takeda, patients are our North Star and those with rare diseases are often underserved when it comes to the discovery and development of transformative medicines, said Andrew Plump, M.D., Ph.D., President, Research & Development at Takeda. Insights from the ground-breaking research of scientists like Prof. Krainer and Prof. Lee can lead to pioneering approaches and the development of novel medicines that have the potential to change patients lives. Thats why we are proud to join with the New York Academy of Sciences to broadly share and champion their workand hopefully propel this promising science forward.

Connecting science with the world to help address some of societys most pressing challenges is central to our mission, said Nicholas Dirks, Ph.D., President and CEO, the New York Academy of Sciences. In this third year of the Innovators in Science Award we are privileged to recognize two scientific leaders working to unlock the power of the genome to bring innovations that address the urgent needs of patients worldwide affected by rare diseases.

About the Innovators in Science Award

The Innovators in Science Award grants two prizes of US $200,000 each year: one to an Early-Career Scientist and the other to a well-established Senior Scientist who have distinguished themselves for the creative thinking and impact of their research. The Innovators in Science Award is a limited submission competition in which research universities, academic institutions, government or non-profit institutions, or equivalent from around the globe with a well-established record of scientific excellence are invited to nominate their most promising Early-Career Scientists and their most outstanding Senior Scientists working in one of four selected therapeutic fields of neuroscience, gastroenterology, oncology, and regenerative medicine. Prize Winners are determined by a panel of judges, independently selected by the New York Academy of Sciences, with expertise in these disciplines. The New York Academy of Sciences administers the Award in partnership with Takeda.

For more information please visit the Innovators in Science Award website.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

About the New York Academy of Sciences

The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With more than 20,000 members in 100 countries around the world, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions and increase the number of scientifically informed individuals in society at large. Please visit us online at http://www.nyas.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005039/en/

See the original post here:
Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners - BioSpace

SHIRLEY, NY, UNITED STATES - Jul 1, 2020 - Recently, exosomes, which have specialized functions and play a key role in different physiological processes and pathological conditions, are attracting increasing attention in their clinical applications for prognosis, diagnosis, drug delivery, and vaccine development. Exosome therapy is also stealing the spotlight in the field of regenerative medicine.

As a well-known participant in the field of exosome research, Creative Biolabs has been establishing a strong network of academic and industrial collaborators, and has optimized its exosome isolation and profiling services in particular.

In the research and application of exosome, the most important step is to isolate them from a wide spectrum of cellular debris and interfering components. Based on well-established technologies and experienced scientists, Creative Biolabs can efficiently separate high-quality exosomes derived from multiple cell types, such as B cells, dendritic cells and tumor cells and almost any biofluid including plasma, urine, serum, CSF, ascites fluid, and saliva, as well as plants.

Creative Biolabs provides different exosome isolation methods for different projects. For example, differential ultracentrifugation, the gold standard method for exosome isolation, is used to isolate exosomes and membrane particles based on their density and size differences from the fluid phase. Exosome precipitation uses the water-excluding polymers such as polyethylene glycol to tie up water molecules and force less soluble components out of solution. Affinity-based Capture and microfluidics-based isolation are also obtainable at Creative Biolabs.

Since exosomes composed of numerous RNA, proteins, lipids, several large-scale analyses such as proteomics and transcriptomics can often be performed. These vesicles also show potential for cancer diagnostics and determination of other diseases because they transport molecular contents of cells from which they originate. Though the detection and molecular analysis of exosomes is technically challenging, Creative Biolabs has a highly experienced team equipped with advanced platforms to achieve a variety of exosome profiling regarding its contents.

In order to obtain expert data interpretation and technical support, Creative Biolabs offers several exosome profiling platforms for the isolation, purification, quantification, and analysis of required exosomes, covering isolation and profiling of exosomal RNA, exosomal cfDNA and exosomal protein as well as exosome-NGS (RNA next generation sequencing).

We own advanced equipment for exosome profiling, such as flow cytometry, electron microscopy and optical microscopy. Introduced by a senior scientist at Creative Biolabs, thus the transferred information of exosomes can be fully explored with our services.

Creative Biolabs provides the best and comprehensive services covering exosome sampling, analysis, manufacturing, and exosome-based application. Besides, a series of high-quality exosome-related products involving all aspects of exosome research, including exosome isolation and purification, exosome qualification, exosome antibody as well as exosome engineering is also available to facilitate clients project success.

Further information can be reached on https://www.creative-biolabs.com/exosome.

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs focuses on offering a full range of exosome-related services and products. With more than a decade of exploration and expansion, Creative Biolabs is now known as a famous institute and experienced supplier in the biotech market, accomplishing numerous challenging projects for customers.

See the rest here:
Creative Biolabs Updated Exosome Isolation and Profiling Service to Facilitate Related Research - Bio-IT World

Newswise Scientists focused on finding better treatments or cures for types 1 or 2 diabetes are painfully aware of current limitations, including having to use animal tissue in studies that often dont translate to human trials.

New research published June 29 in Nature Communications could help researchers overcome some of the biggest challenges of taking diabetes research from the lab to human trials and the clinic.

By using a technology first developed at the University of Miami Miller School of Medicine along with a Miller School patented approach to enhance the oxygenation of cultured tissues, researchers will likely be able to conduct real-time regeneration and development studies in the human pancreas.

The finding could lead to treatments that regenerate ones own pancreas without the need for transplantation, according to the studys senior author Juan Domnguez-Bendala, Ph.D., director of stem cell development for translational research and associate professor of Surgery at the Diabetes Research Institute, University of Miami Miller School of Medicine.

Dr. Bendala explained that in people who have type 1 diabetes, the bodys own immune system kills beta cells, or islet cells, in the pancreas that make insulin. Doctors have for years transplanted donor islet cells to replenish those cells.

But there are challenges to the approach. One is a scarcity of donors for organ transplantation. Another is when transplanting the islet cells is possible, the recipients body will likely reject the donor cells unless the recipient is immunosuppressed. Immunosuppression, alone, leads to complications.

The two pillars of our research are to replenish the islet cells that have been lost and then to stop autoimmunity, which is the underlying cause of the disease, Dr. Bendala said. We also are interested in using endogenous regeneration. We have found that there are pancreatic stem cells that we call progenitors because they already have committed to become part of the pancreatic tissue. Ultimately, we want to induce them to replicate and give rise to new insulin-producing cells within the patient, instead of transplanting beta cells from an external source.

Human pancreatic slices are very thin slices of the pancreas that keep together the organs natural architecture, including the much-needed islets.

The islets in these slices are surrounded by acinar cells, which make the digestive juices in the pancreas, and more importantly the ducts, where we have found the progenitor stem cells that can give rise to new beta cells, Dr. Bendala said. Thats why these slices are a very powerful tool to study the organ. Its as if you had a window into the living pancreas.

The problem when studying the regenerative process in human pancreatic slices has been that the tissue lasts only a couple of days before disintegrating and dying.

Dr. Bendala and colleagues determined that the main reason for cell death in the slices was a lack of oxygen. The pancreas is a very vascularized organ, and slicing it cuts off its blood supply.

Dr. Bendala and coauthor on the Nature Communications paper Ricardo Pastori, Ph.D., research professor of medicine, immunology, and microbiology and the director of the Molecular Biology Laboratory at the Diabetes Research Institute, circumvented the problem by placing human pancreatic slices in a culture device they invented that uses a perfluorocarbon (PFC) membrane.

PFC is a compound that is so rich in oxygen that you can breathe it in its liquid form, Dr. Bendala said. We have published on this device and shown that islets survive and function much better when we culture them on PFC. And when we differentiate stem cells into beta cells, the process occurs much more efficiently when you put them in PFC. It was no surprise that when we placed the human pancreatic slices into the PFC membrane that they survived and did much better than controls. We could keep them alive for about 2 weeks, some went as long as 3 weeks, and they were fully functional during that time.

Keeping human pancreatic slices alive for that long is a major breakthrough in diabetes research, especially in the area of islet cell regeneration, he said.

You need a model when you study regeneration. Traditionally we have used the mouse model, and, unfortunately what happens in mice in the lab often doesnt pan out in humans, Dr. Bendala said. This work is revolutionary because using these human pancreatic slices we can witness and monitor regeneration in a human model that resembles a real organ. That was not possible before because the tissue simply didnt live long enough.

The Miller School researchers also tested a molecule called BMP-7, which they have shown in previous studies to act as fuel to stem cells. They showed in this paper that BMP-7 can induce proliferation of pancreatic progenitors in human pancreatic slices.

When we added BMP-7 to human pancreatic slices, we could detect progenitor cells activating, proliferating and then giving rise to new beta cells. We could see that happening before our very eyes, he said.

The fact that the study also included tissue from human type 2 and type 1 diabetic patients makes it more much more likely that the research will facilitate progress to human clinical trials.

I took a step back when I saw this for the first time. This was a living human pancreatic slice from a patient who had passed 10 days ago, he said. I couldnt help but think, imagine if we had done this in the patient if he or she was still alive? Its really powerful.

Dr. Bendala sent PFC-based dishes at no cost to several other centers conducting diabetes research, so they could study the approach and potentially replicate the findings. In the meantime, Dr. Bendala and Miller School colleagues are screening molecules other than BMP-7 to see if they have potential to create new beta cells by inducing progenitors or by inducing the replication of pre-existing beta cells.

The goal is to have a therapy to present to the FDA to produce beta cells within a few years.

These technologies will greatly accelerate our ability to decide what is going to work in clinical trials, he said.

Continue reading here:
University of Miami Miller School-led technology paves way for islet regeneration in human pancreas - Newswise

3D Bioprinting Market Size, Growth, Trends and Share Analysis By Technology (Microextrusion Bioprinting, Inkjet 3D Bioprinting, Laser-assisted Bioprinting, Magnetic 3D Bioprinting), Material (Living Cells, Hydrogels, Extracellular Matrices), End-user and Region, Forecast To 2023

Global3D Bioprinting Marketsize is projected to reachUSD 1,923.02 Millionwith expanding at aCAGR of 24.59%By 2023. Currently, the 3D bioprinting is used to print tissues & organs and in the drug discovery. 3D Bioprinting is an emerging technology, which has the potential to transform the medical field with its capacity to bio fabricate living tissues & organs by combining a patients own cells with other biomaterials. Moreover, researchers, innovators, and early adopters are improving the performance of this disruptive technology stepwise, as it grows. The 3D bioprinting market is growing pervasively, mainly due to the burgeoning medical implant market.

The 3D bioprinting majorly involves the creation of simple tissue structures in lab settings. However, in the future, the technology is estimated to participate in the production of complete organs for transplants. It would also be used for swifter and more accurate drug testing. As potential drug compounds could be tested on bio-printed tissue before human trials have begun.

Request Free Sample Report at:https://www.marketresearchfuture.com/sample_request/869

Global 3D Bioprinting Market Segmentations:

The 3D bioprinting market is segmented by Technique, Application, Material and End User

By Technique the global 3D bioprinting market has been segmented intomicroextrusion bioprinting, inkjet 3d bioprinting, Magnetic 3d bioprinting and laser-assisted bioprinting.

By Application 3D bioprinting market has been segmented into Research (regenerative medicine, personalized healthcare, 3D cell culture, others) and Clinical (tissue transplantation, bone grafts, wound care, vascular grafts, others), among other several applications.

By Material3D bioprinting markethas been segmented intoExtracellular Matrices, Cells, Fibrinogen, Alginate, and Hydrogels, among others.

By End-user 3D bioprinting market has been segmented into Academic Institutes and Biotechnology Companies, among others.

Global 3D Bioprinting Market Regional Analysis:

North Americacommands the global market with largest 3D bioprinting market share. The presence players like Organovo Holdings, Inc. & Stratasys Ltd. and well-developed healthcare sectors in the region, drive the North American 3D bioprinting market growth. Besides, high healthcare expenditures, favorable government regulations, and huge patient population for organ transplantation boost the growth of the regional market. With the growing biotech sector, the North American 3D bioprinting market growth is expected to continue with its dominance in the years to come.

Europetakes the second largest global 3D Bioprinting market share. Factors such as the increased research & development activities driven by government support and funds are substantiating the regional 3D Bioprinting market growth. Heading with the increasing per capita healthcare expenditures in Germany, the UK, and France, the region is expected to grow during the forecast period.

TheAsia Pacific3D bioprinting market is emerging as a promising market globally. Vast patient pool and the burgeoning medical treatment market in the region attribute to the growth of the market. Growing 3D bioprinting markets in India and China, backed by the increasing awareness & improved lifestyle, provide impetus to the regional market surge. Besides, the improving economy in the region is expected to create opportunities in the 3D Bioprinting market during the forecast period.

Global 3D Bioprinting Market Competitive landscape

Highly competitive, the 3D bioprinting market appears to be fragmented with several players accounting for a substantial market share. To gain a substantially larger share in the market, these players incorporate strategic initiatives such as acquisitions & mergers, collaboration, expansion, and product & technology launch. Expansion in the emerging market helps them to extend their sales networks. On the other hand, some of the players appear to be reluctant to collaborate as engineering firms & suppliers do not provide CAD drawings/input to clients due to the risk of losing IP.

Major Players:

Players leading the 3D bio-printing market includeCellink AB (Sweden), Organovo Holdings, Inc. (US), Bio3D Technologies (Singapore), Stratasys Ltd. (US), Aspect Biosystems Ltd. (Canada), Fathom (US), Materialise (US), Envisiontec, Inc. (Germany), Allevi (US), Nano3D Biosciences, Inc. (US), 3Dynamic Systems Ltd. (UK), Cyfuse Biomedical KK (Tokyo), REGENHU (Switzerland), and Poietis (France), among others.

Industry/ Innovation /Related News:

CollPlant (the US), a 3D bioprinter material developer, announced the receiving an investment of USD 5.5 MN provided by a group of investors with a special interest in the 3D printing industry and from one its largest shareholder Ami Sagi.

CELLINK (Sweden), a 3D bioprinter and materials developer, launched a new six-printhead bioprinting system named BIO X6. The new six-printhead 3D bioprinting platform allows the combination of multiple materials, cells, and tools, featuring an intelligent exchangeable printhead system and CELLINKs patented Clean Chamber Technology to enhance advanced research & clinical applications.

inkClub AB (Sweden), an online retailer, announced the acquisition of 3D PRIMA (Sweden), an online store for 3D-Printers and filaments. 3D Prima is a fast-growing e-commerce player, and inkClub was one of the first to sell 3D-printing products online. The acquisition is aligned with inkClubs strategic initiative for expansion. InkClub has both the experience and e-commerce expertise, which is essential when 3d Prima, is growing.

Browse Full Report Details at:https://www.marketresearchfuture.com/reports/3d-bioprinting-market-869

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

Follow this link:
3D Bioprinting Market Size Is expected to Reach USD 1923.02 Million at a CAGR of 24.59% By 2023 - Cole of Duty

The healthcare workers rely on personal protective equipment to protect themselves and their patients from being infected and infecting others. But shortages of such PPE are leaving doctors, nurses and other frontline workers dangerously ill-equipped to care for COVID-19 patients, due to limited access to supplies such as gloves, medical masks, respirators, goggles, face shields, gowns, and aprons. The World Health Organization has warned that severe and mounting disruption to the global supply of personal protective equipment (PPE) caused by rising demand, panic buying, hoarding and misuse is putting lives at risk from the new coronavirus and other infectious diseases. As the number of COVID-19 cases continues to grow worldwide, political leaders are encouraging physical (or social) distancing to slow the rate of transmission. The goal of this practice is to flatten the curve of a new infection, thereby avoiding a surge of demand on the health care system, but the effects of physical distancing may take weeks to appear.

For a detailed analysis of the Healthcare PPE demand during COVID-19 impact browse through:https://univdatos.com/report/global-healthcare-ppe-demand-analysis-covid-19-impact-feb-dec-2020

Healthcare Personal Protective Equipment manufacturers are racing to boost production of the medical PPE required to save the lives of many critically ill COVID-19 patients, but they will not be able to ramp up production quickly enough to meet the demands of the exponentially growing cases of COVID-19. 3M Company, Dowdupont, MSA Safety, Honeywell International, Ansell Limited are among the largest suppliers of medical personal protective equipment, and these are working day and night to meet increased global demand. For instance: Since January, 3M has doubled production of N95 respirators to 1.1 billion per year at its global manufacturing facilities, including in the U.S., Asia and Europe. 3M aims to double its capacity again to 2 billion per year within the next 12 months. In this crisis, 3M is experiencing an unprecedented surge in demand for N95 respirators, and demand will outpace supply for the foreseeable future.

For a detailed analysis of the product type development to cater to the increasing Healthcare PPE demand during COVID-19 impact browse through:https://univdatos.com/report/global-healthcare-ppe-demand-analysis-covid-19-impact-feb-dec-2020

Across the world, frontline medical staff is clamoring for face masks and other personal protective equipment (PPE). In the United States, the new epicentre of the pandemic, shortages are so acute that health workers have taken to social media to appeal for help under the hashtag. Frontline medical staff in many countries say shortages of masks and other equipment have left them vulnerable to catching the virus which forces them into isolation and reduces staff numbers. There are two main kinds of mask: The surgical masks worn routinely on many Asian streets, which can provide some protection; and the higher-standard respirators, often known by designations such as N95 or FFP (filtering facepiece), which are meant for medical procedures to protect workers from the droplets through which the virus spreads. The demand for all of them has skyrocketed. Besides, the government is taking initiatives regarding healthcare PPE production given rising COVID-19 cases across the world. NSW Health is implementing a state-wide strategy to ensure all staff has the personal protective equipment needed to protect them at work by collaborating with the Federal Government to access the national medical stockpile and seeking alternative supply chains. UNICEF Spain has donated 418,000 face masks to the Government of Spain in support of the national response on COVID-19. Announcing Indian Railways foray into another major COVID-19 relief initiative, Minister Piyush Goyal states that it will soon begin large-scale manufacturing of Personal Protective Equipment (PPE) kits to augment their supply amidst a growing demand while at the same time, ensure that Indias medical staff are adequately equipped to fight COVID-19.

Request for Sample of the report browse through https://univdatos.com/request_form/form/323

For a better understanding of the Healthcare Personal Protective Equipment, demand trend arises due to COVID-19, a detailed analysis was conducted for the top 10 most affected regions including United States, Canada, Germany, United Kingdom, France, Italy, Spain, Turkey, Iran, and India. The United States currently has the highest number of healthcare personal protective equipment available and is expected to need even more than any other country across the world as the region acquires more than 33% of the global COVID-19 cases alone and the cases are still on the rise. Some of the major players profiled in the Healthcare Personal Protective Equipment demand market study include 3MCompany, Kimberly-Clark Corporation, Ansell Limited, Honeywell International, Alpha Pro Tech, MSA Safety, DuPont Inc., Lakeland Industries, Avanos Medical, and Medline Industries. These industry players are entering into several mergers & acquisitions and partnerships for the expansion of their reach and increasing their hold on the market.

Global HealthcarePPEDemand- COVID-19 Impact, Market Segmentation

Market Insights, by Product Type

Medical Masks

Gowns

Gloves

Goggles

Market Insights, by End-Users

Hospitals

Primary Care Facilities

Others

Market Insights, by Countries

United States

Canada

Germany

United Kingdom

France

Italy

Spain

Turkey

Iran

India

Rest of World

Top Company Analysed

3M Company

Kimberly-Clark Corporation

Ansell Limited

Honeywell International

Alpha Pro Tech

MSA Safety

DuPont Inc.

Lakeland Industries

Avanos Medical

Medline Industries

Feel free to contact us for any queries https://univdatos.com/request_form/form/323

Global Healthcare PPE Demand Analysis-COVID-19 Impact reportcan further be customized as per the clients requirements (interested country). Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

Regenerative Medicine Market to represent a significant expansion at CAGR of 31.5% for the period of 2020 to 2026

Frozen Foods Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020-2026

Self Service Technology Market Expected to Grow at a CAGR of 10.7% During the Forecast Period 2020-2026

About Us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. Rigorous secondary and primary research on the market is our USP, hence information presented in our reports is based on facts and realistic assumptions. We have worked with 200+ global clients, including some of the fortune 500 companies. Our clientele praises us for quality of insights, In-depth analysis, custom research abilities and detailed market segmentation.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

See the original post here:
COVID-19 Impact on Healthcare Personal Protective Equipment (PPE Kits) Market (2020-2026) | Emphasis on Product Type (Medical Masks, Gowns, Gloves,...

As we discussed in our last update on the Food and Drug Administrations Comprehensive Regenerative Medicine Policy Framework back in December 2019 (during the much simpler, pre-COVID-19 world), this coming November will conclude the three-year period of enforcement discretion announced by the agency when it first articulated the policies and goals of this comprehensive framework. In particular, under the dual-track program announced in 2017, the Food and Drug Administration (FDA) has been focused on: (1) clarifying the regulatory criteria for product marketing through guidance and providing support to legitimate product developers through formal and informal interactions; and (2) removing unapproved, unproven, and potentially unsafe products from the U.S. market.

None of the COVID-19-related operational updates provided by the FDA generally or by the Center for Biologics Evaluation and Research (CBER) in recent months has suggested that the November 2020 deadline will be extended or otherwise altered as a result of the ongoing public health emergency, even as certain other enforcement discretion policies have been put into place. Additionally, a recent editorial published by agency leadership and a noticeable increase in Warning/Untitled Letters to persons offering unapproved cellular therapy products, taken together, strongly suggest that folks in this industry that are currently operating outside of the applicable regulatory framework should not expect to be given any additional time to come into compliance.

June 2020 JAMA Editorial Strong Language and No Sign of a Deadline Extension

Multiple statements on the topic of regenerative medicine have been issued by the governing FDA Commissioner as well as CBER Director Peter Marks over the past several years, which indicates how important this area is to the agencys broader public health priorities at the start of the 21st century. The most recent salvo from agency leadership came in the form of an editorial published online by JAMA on June 17, 2020, authored by Dr. Marks and Commissioner Stephen Hahn, who has been in his new job for about six months. Their editorial includes some of the strongest language we have seen to date on the topic of unapproved regenerative medicine products. For example, Dr. Marks and Dr. Hahn state that [d]espite assertions by some individuals to the contrary, these products, whether autologous or allogeneic, are not inherently safe and may be associated with serious adverse consequences. They assert that [t]he increasing number of adverse events being reported following the widespread use of unapproved regenerative medicine therapies at hundreds of clinics across the country make it necessary for the FDA to act to prevent harm to individuals receiving them.

Drs. Marks and Hahn briefly highlight some of the enforcement that the agency has undertaken in this space since 2017 and ask for engagement from both clinicians and patients to help to ensure that instead of remaining unintentionally or intentionally hidden, potentially harmful unapproved regenerative medicine therapies are identified and removed from the market. They then provide basic guidelines for patients and caregivers to use when assessing whether a cellular therapy product is being offered in compliance with applicable laws and FDA regulations. Specifically, they recommend the following key considerations for anyone considering treatment with a cellular product:

Nothing in this newly-published editorial suggests that FDA/CBER will be taking its proverbial foot off the pedal to slow down its efforts towards further oversight of the private stem cell clinic industry after November 2020. To the contrary, the piece could represent one of the last informal warnings those businesses get from the agency before they receive a customized Warning or Untitled Letter or become subject to whatever increased enforcement activity the federal government initiates in this area in 2021 and beyond.

Relatively Large Number of Warning Letters Sent Since January 2020

We previously noted that FDA/CBER appeared to have increased the pace of issuing Warning and Untitled Letters to sellers of unapproved stem cell products during the second half of 2019, with many of those letters involving companies that processed and marketed unapproved umbilical cord blood-derived cellular products. We also reported that the agency had issued a Public Safety Notification on Exosome Products on December 6, 2019, informing the public of multiple reports of serious adverse events experienced by patients in Nebraska who were treated with unapproved products marketed as containing exosomes. That safety alert also described the unscrupulous conduct of sellers of such products in forceful and direct language, similar to the language used by Dr. Marks and Commissioner Hahn in this months editorial piece.

Over the first half of this year, as we get yet closer to the November 2020 deadline for stem cell clinics and medical practitioners to come into compliance with federal law, there has been a more noticeable increase in the Warning/Untitled Letters issues regarding the marketing of unapproved products that put patients at risk. These include at least nine Untitled Letters issued since January 2020 (which can each be accessed from this CBER webpage) and at least two Warning Letters, one from March and one from June. The Warning Letters in particular include charges that the firms in question were violating current good manufacturing practices (CGMPs) and current good tissue practices (CGTPs) for human cells and tissue products, putting patient safety at risk.

Interestingly, the most recent FDA Warning Letter issued on June 4, 2020 not only cites the recipient for marketing unapproved stem cell products and an unapproved exosome product, but it also states that the unapproved exosome product was being marketed for the treatment and prevention of COVID-19 something the June 17 Marks/Hahn JAMA editorial alluded to generally as well. Given that there are currently no FDA-approved products to prevent or treat COVID-19, any such claims will automatically heighten the enforcement risk to a company or physician engaged in the sale of products for those intended uses.

In addition to the work being done by FDA, moreover, the Federal Trade Commission (FTC) has also been monitoring the commercial marketplace closely and taking various actions to protect consumers from fraudulent COVID-19 products, including a few marketed by stem cell clinics. So far this month, FTC announced on June 4, 2020 that it had issued a 35 warning letters and an additional 30 warning letters on June 18, 2020. The first batch of these FTC warning letters notably included one to a stem cell clinic that, among other things, had claimed that stem cells can be administered intravenously and by inhalation through a nebulizer to treat lung damage caused by COVID-19 without scientific evidence to support the efficacy claim, while the second batch included two letters addressed to marketers of stem cell products.

FDA and the FTC coordinate quite closely on consumer protection matters that implicate both agencies primary missions, as is apparent from the large number of COVID-19 Warning Letters that have been jointly issued by the two agencies since March 2020. So they may very well be coordinating more actively now on the monitoring of stem cell clinics and individual physicians offering unapproved cellular therapies to the general public, as the focus shifts to the next phase of the Comprehensive Regenerative Medicine Policy Framework. The next five or six months should offer everyone more insight into what the enforcement landscape is likely to evolve into once the FDAs enforcement discretion period ends in November. As always, well keep our readers apprised of any notable developments.

[View source.]

Read more from the original source:
Update on FDAs Comprehensive Regenerative Medicine Framework: Looming November 2020 Deadline Preceded by a Flurry of Letters from CBER and a New JAMA...

LONDON--(BUSINESS WIRE)--Infiniti Research is the world's leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed to connect your organizations goals with global opportunities. Today's competitive business environment demands in-depth, accurate, and reliable business information to ensure that companies gain a strong foothold in domestic or foreign markets. Our global industry specialist teams ensure the international consistency of our research, enabling powerful access to the real story behind market changes. Request a free brochure for more insights into our solutions portfolio.

Regenerative medicine is currently the hive of innovation in modern science with far-reaching benefits for big pharma, healthcare systems, and patient outcomes. The rapid pace of development is expected in the US regenerative medicine market over the next decade. Some of the key factors fueling demand include the increasing investments in R&D activities and the rising incidence of chronic diseases in the country. Leading vendors have enhanced their R&D investments to develop innovative medical therapies, which is driving the overall growth of the market. Furthermore, M&A and strategic alliances among vendors will have a significant impact on the overall market growth and innovation. Nevertheless, the actual delivery of regenerative medicines has proven to be rather challenging with several roadblocks to commercially viable therapies that are capable of catering to unmet clinical needs.

The promise of regenerative medicines requires an innovative look at the complete product lifecycle, including the development of an efficient distribution network. Planning to venture into this space? Request a free proposal for comprehensive insights about the market.

Experts at Infiniti Research outline some of the most relevant and pressing manufacturing challenges in regenerative medicine products:

Manufacturing expense: Cell therapy manufacturing processes are generally highly expensive. Scaling up from limited laboratory facilities to automated systems for bulk production will largely be based on cost, therefore impeccable financial and time planning become vital.

Design quality: In the case of automation, robots manually reproduce the existing inefficient manual processes due to which the products are often based on obsolete technologies. As a result, the manufacture of regenerative medicines sometimes misses the opportunity to improve their quality by innovating process design.

Biomaterials challenges: Challenges relating to biomaterials are mostly concerned with their selection than the manufacturing process. The trends in material selection will eventually have a major impact on the manufacturing process.

Supply chain challenges: The clinical supply chains required to deliver regenerative medicines therapies are arguably the most complex the industry has seen so far, even more so than for biologic medicine.

Read the complete article for comprehensive insights on the key regenerative medicine manufacturing challenges.

The personalization and unique requirements of regenerative medicines require manufacturers to provide an increased focus on the precision and accuracy of processes. Get in touch with an industry expert from Infiniti research to identify gaps in your existing processes and bridge them with viable business strategies.

About Infiniti Research

Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies. To know more, visit: https://www.infinitiresearch.com/about-us

See the article here:
Regenerative Medicine: The Future of Medicine is Here but Not Without Challenges | Infiniti Research - Business Wire

Overview: Regenerative medicine is an interdisciplinary field that applies life science and engineering principles for the regeneration or repair of injured/diseased tissues or organs resulting from various causes including, disease, defects, trauma and aging. The field includes the generation and use of tissue engineering, therapeutic stem cells and the production of artificial organs. It also allows scientists to grow organs or tissues in the lab and implant them in the body safely when the body fails to heal itself. Notably, it has great potential to solve the problem of organ shortage.

Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/9918

According to the estimation of World Health Organization, there is an increasing prevalence of diabetes among adults over the age of 18 years, that has increased to 8.5% in 2014 compared to 4.5% in 1980 across the globe. As per the estimation of Arthritis Foundation, the number of people expected to be diagnosed from arthritis will be more than 78 million, by 2040.

The market for regenerative medicine is driven by increasing prevalence of neuronal disease, cancer and genetic disease, emerging application of regenerative medicine, and advancement in technology. Huge number of ongoing clinical trails and strong product pipeline are providing market growth oppurtunity. High cost of the treatment, regulatory issues and ethical issuesare hampering the market growth.

Market Analysis: The Global Regenerative Medicine market is estimated to witness a CAGR of 16.6% during the forecast period 20182024. The global market is analyzed based on three segments Therapy, Application and regions.

Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global regenerative medicine market, followed by Europe. Asia-Pacific region is expected to have the fastest growth rate with the market growth centered at Japan, China and India. This is mainly due to increasing funding in healthcare research, rising research activities, growing patient pool, flexible regulatory environment for clinical trials, and rising healthcare expenditure.

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/9918

Therapy Analysis:Immunotherapy occupied major market share of global regenerative medicine market in 2017, and is expected to remain same during the forecasted period. Increasing product approvals, emerging technological advancements in cell and gene therapy, flexible regulatory for stem cell based research, and growing awareness regarding the benefits of stem cell therapies.

Application Analysis: The market by application is segmented into cancer, central nervous system, orthopedic and musculoskeletal, diabetes, dermatology, cardiovascular and others. Among various application, dermatology occupied the largest share in 2017 and cancer segment is expected to grow at fastest rate during the forecasted period. Growing aging population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.

Key Players: Allergan plc, Integra lifesciences, Mimedx Group, Inc., Medtronic plc, Organogenesis Inc., Zimmer Biomet, Acelity L.P. Inc., Nuvasive, Inc., Stryker Corporation, Japan Tissue Engineering Co., Ltd. (Fujifilm Holdings Corporation subsidiary), Osiris Therapeutics, Inc., Vericel Corporationand other predominate and niche players.

Competitive Analysis: Currently dermatology segment dominates the global regenerative medicine segment. A lot of researches are going on cancer, CNS, cardiovascular, orthopedic & musculoskeletal applications. The increasing importance of regenerative medicine has resulted in the launch of new products and also increased acquisition, approvals, funding to develop new product.

For instance, in August 2017, Tissue Regenix Group plc completed the acquisition of acquisition of CellRight Technologies, an US based specialist in regenerative osteoinductive bone scaffolds. In April 2018, Roche acquired a program named Inception 5, focused on regenerative therapies for multiple sclerosis. In May 2018, Novartis received second FDA approval for Kymriah, CAR-T cell therapy for B-cell acute lymphoblastic leukemia (ALL)

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/9918

Benefits: The report provides complete details about the usage and adoption rate of regenerative medicine in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

The rest is here:
Regenerative Medicine Market to Record a Robust Growth Rate for the COVID-19 Period - Cole of Duty

An online game that lets students learn about stem cells and tissue engineering also offered them information about high school and college internship programs to further spur their interest in regenerative medicine.

Through the game, aimed mainly at seventh graders through high school seniors, students competed in daily challenges to win swag and the chance to meet inventor Dean Kamen (virtually in this pandemic age).

The vision is to help inform young people about all the really cool things that are happening in this space, said Alexander Titus, the freshly minted chief strategy officer at the Advanced Regenerative Manufacturing Institute in Manchesters Millyard.

The game helps to inspire students as they choose their classes, their elective classes in high school and particularly majors in college, Titus said last week.

Nearly 100 students took part in the game, which ended Friday. The content about regenerative medicine will remain online through June.

ARMI, which is working to manufacture human tissue commercially, is working on recruiting tomorrows workforce one cool video at a time.

I think the timing of this couldnt be any better, said Julie Demers, executive director of the New Hampshire Tech Alliance. The pandemic has limited in-person, work-based learning opportunities and interactions with industry professionals. Interactive opportunities to get students interested in and thinking about career opportunities are critical.

Titus said a chief goal is to build a pipeline of future workers.

Its all tied together in attracting students while theyre young to understand the process of what to study along the way to get to college and a job when theyre done, said Titus, who earned a Ph.D. in quantitative biomedical sciences at Dartmouth.

Titus said he expects the game to help ARMI officials learn what draws the interest of students so they can develop other programming they know will garner student interest, he said.

The ARMI challenge, called TEMPtation, featured profiles of businesses from more than a dozen states as well as universities and colleges interested in regenerative medicine.

Arizona State University holds summer camps for middle and high school students that are interested in learning more about science and mathematics, read one profile.

From Georgia Tech in Atlanta: Georgia Tech has a Center for Career Discovery & Development, which offers internships, co-ops, and career services that give students the resources they need to support their search for employment following their graduation.

Formerly employed at the U.S. Department of Defense, Titus returned to New Hampshire to join ARMI.

The mission, he said, is marrying science and manufacturing.

Bring the science to the stage where we can automate it and market the new technologies we couldnt make before, said Titus, previously assistant director for biotechnology within the Office of the Under Secretary of Defense for Research & Engineering.

ARMI features more than 150 partners and more than $300 million in government and private investment committed.

If we want to be able to produce a replacement heart for people who have heart disease, what are the components that go into that? Titus said.

He hopes ARMI can attract startups in the Manchester area, allowing for ARMI to mentor them until they are viable companies.

The idea is for companies to move into New Hampshire and move into our ecosystem if you will, Titus said.

I think especially given now, where were seeing so many people in the cities during COVID have a hard time social distancing, I expect well see some shifting of people out of the cities, said Titus, who speculated some could settle in New Hampshire.

Whats Working, a series exploring solutions for New Hampshires workforce needs, is sponsored by the New Hampshire Solutions Journalism Lab at the Nackey S. Loeb School of Communications and is funded by Eversource, the New Hampshire Charitable Foundation, Dartmouth-Hitchcock Medical Center, the New Hampshire College & University Council, Northeast Delta Dental and the New Hampshire Coalition for Business and Education. Contact reporter Michael Cousineau at mcousineau@unionleader.com. To read stories in the series, visit unionleader.com/whatsworking.

Visit link:
Online game looks to stoke interest in regenerative medicine - The Union Leader

he globalstem cell and regenerative medicines marketshould grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

More Info of Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11723

Read more:
Stem Cell And Regenerative Therapy Market : Segmentation, Industry Trends and Development size COVID-19 2024 - 3rd Watch News

Wearing masks and other personal protective equipment (PPE) can slow the spread of COVID-19. The U.S. Centers for Disease Control and Prevention recommends everyone wear some kind of face covering in public places, especially where social distancing is difficult to maintain. And health workers are donning additional coverings, such as gowns. Yet all such protective gear shares one significant problem: people still risk becoming infected with the novel coronavirus if they accidentally touch areas of the fabric that are contaminated with viral particles. So researchers are working to develop cloth that could inactivate or repel coronavirusesideally including the one that causes COVID-19and other pathogens.

People can transfer infectious particles to their hands if they touch the front of a mask during use or when they remove gowns or other PPE, according to Chandan Sen, director of the Indiana Center for Regenerative Medicine and Engineering at Indiana University. He and his colleagues have been developing a way to render those particles and other infectious agents harmless. The team researches electroceutical materials that wirelessly generate electric fields across the surface of the fabric, Sen says. Those fields can disrupt the behavior of bacteria or viruses on the cloth.

The beauty of this [technology] is the inherently simple design, he says. The polyester material is printed with alternating spots of silver and zinc resembling polka dots. They are one to two millimeters wide and spaced one millimeter apart. When the electroceutical material is dry, it functions as an ordinary fabric. But if it gets dampenedsay, with saliva, vapor from a coughed up droplet or other bodily fluidsions in the liquid trigger an electrochemical reaction. The silver and zinc then generate a weak electric field that zaps pathogens on the surface.

The researchers co-developed the material with the biotechnology company Vomaris Innovations in 2012. Last year they showed that the technology could be used to treat bacterial biofilms in wounds. A clinical trial is underway to further evaluate the fabrics effectiveness as a Food and Drug Administrationcleared dressing for wound care, Sen says.

In response to the COVID-19 pandemic, Sens team tested its existing material on a different coronavirus strain that causes a respiratory illness in pigs and on an unrelated type of pathogen called a lentivirus. We wanted to know how broadly this principle could be applicable, he says. In a study posted on the preprint server ChemRxiv in May, Sens team reported that its electroceutical fabric destabilized both viruses, leaving them unable to infect cells. The researchers plan to submit the results to a peer-reviewed journal as well.

To study the fabrics action, they placed a liquid solution containing viral particles onto the electroceutical fabric and a polyester control fabric without the metal dots. After the droplets were fully absorbed, and the samples had rested for one to five minutes, the researchers recovered viral particles from both fabrics and tested whether they could still infect the types of cells they typically target.

The data presented here show that, of the total virus that was recovered, a significant percentage was inactivated, says Jeff Karp, a professor of medicine at Brigham and Womens Hospital in Boston and co-leader of an N95 respirator working group at the Massachusetts General Brigham Center for COVID Innovation. Karp, who was not involved with the study, adds that the researchers did not test all of the virus that they had placed on the cloth. In fact, the majority of virus was not recovered from the textiles examined in this study, he says. Sen responds that his team focused on sampling only enough viral particles to show that the fabric had rendered them unable to infect cells. The researchers recovered roughly 44 percent of the particles from the electroceutical fabric samples that had rested for one minute. And they retrieved 24 percent of them from the samples that had rested for five minutes.

The materials virus-fighting abilities have not been tested specifically on SARS-CoV-2, the coronavirus that causes COVID-19. The researchers findings with the two viruses they studied, however, gave them hope that this could apply more widely, Sen says. He adds that large-scale manufacturing of the electroceutical fabric is already possible and that the costs of producing it are relatively low. The metal dots could be printed directly onto the front surfaces of masks, he suggests. Or an electroceutical fabric could be inserted between the front of a mask and the wearers face.

If a virus-stopping PPE material were widely available, it could limit the novel coronaviruss ability to spread. There is a huge unmet need to better understand modes of viral transfer that lead to virus transmission, Karp says. As we develop a better understanding of this, there is a huge immediate need to develop and quickly apply solutions that can reduce transmission.

Metal dots are not the only potential approach. Paul Leu, director of an advanced materials laboratory at the University of Pittsburgh, and his colleagues are developing a textile coating that repels bodily fluids, proteins and bacteria. It also repels one strain of adenovirus that causes respiratory illness and another that causes conjunctivitis, as reported in ACS Applied Materials & Interfaces in April. Leus team has also not tested the material with the novel coronavirus itself, however. The main thing with testing [the coating on] SARS-CoV-2 is the biosafety level you need to test it, because its very hazardous, he says. Still, his team plans to see how well textiles with this coating repel a different coronavirus.

Leu says the coating, which remains repellent even after ultrasonic washing and scraping with a razor blade, could make PPE safer for wearers to take off. It could also be used on hospital bed linens, drapes and waiting room chairs, the researchers note in the study. But Leu points out that the coating is intended for use with medical textiles that are already considered reusable. His team has not tested it on single-use masks or N95s, but he thinks it could potentially damage them. Still, he says, the coating could work well for cloth masks such as those now being worn by many among the general public.

By developing materials that kill or repel viruses, researchers hope to make masks and other protective gear safer to remove and more effective against all viruses. If the common person were to have PPE that wouldnt spread infection, Sen says, I think thats a big, big deal.

Read more about the coronavirus outbreakfromScientific Americanhere. And read coverage from ourinternational network of magazines here.

Read the original here:
Electrified Fabric Could Zap the Coronavirus on Masks and Clothing - Scientific American

CHICAGO, June 23, 2020 /PRNewswire/ -- According to the new market research report "Biopreservation Market by Type (Media (Sera), Equipment (Thawing Equipment, Alarms, Freezers)), Biospecimen (Human Tissue, Stem Cells, Organs), Application (Therapeutic, Research, Clinical Trials), End User (Hospitals, Biobank) - Global Forecast to 2025", published by MarketsandMarkets, the Biopreservation Market is projected to reach USD 4.9 billion by 2025 from USD 3.1 billion in 2020, at a CAGR of 9.1% between 2020 and 2025.

MarketsandMarkets Logo

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=842

Increasing R&D investments, advances in biobanking and the growing trend of conserving cord blood stem cells of newborns, rising investments in regenerative medicine research, and the increasing demand for personalized medicine are the major factors driving the growth of the biopreservation media and equipment market.

The biopreservation media segment accounted for the largest share of the biopreservation media and equipment market.

Based on type, the biopreservation media and equipment market is segmented into biopreservation media and equipment. The biopreservation media segment accounted for the largest share of the global biopreservation media and equipment market in 2019. The large share of this segment is attributed to the increasing research activities in stem cell therapy, regenerative medicine, and personalized medicine.

Browsein-depth TOC on"Biopreservation Market"

286 Tables 35 Figures233 Pages

The human tissue samples segment accounted for the largest share of the biopreservation media and equipment market in 2019.

On the basis of biospecimen, the biopreservation media and equipment market is segmented into human tissue samples, organs, stem cells and other biospecimens. The human tissue samples segment accounted for the largest share of the global biopreservation media and equipment market in 2019. The large share of this segment is attributed to the increasing number of biobanks and growth in R&D spending for life science research.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=842

North America to dominate the biopreservation media and equipment market during the forecast period

In 2019, North America dominated the biopreservation media and equipment market, followed by Europe. The major factors driving the growth of this market include increasing research activities in the field of regenerative medicine, rising R&D investment in life sciences research and growing awareness of personalized medicine.

The prominent players in this market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Avantor, Inc. (US) ThermoGenesis Holdings, Inc. (US), Bio-Techne Corporation (US), BioLife Solutions, Inc. (US), Exact Sciences Corporation (US), (US), Worthington Industries, Inc. (US), and Chart Industries, Inc. (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=842

Browse Related Reports:

Biobanking Marketby Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) - Global Forecast to 2022

Story continues

https://www.marketsandmarkets.com/Market-Reports/biobanking-devices-market-594.html

Lab Automation Marketby Equipment and Software (Robotic Arms, Microplate Readers, LIMS), Applications (Drug Discovery, Clinical Diagnostics, Genomics), End Users (Biotechnology and Pharmaceuticals, Diagnostic Labs) - Global Forecast to 2022

https://www.marketsandmarkets.com/Market-Reports/lab-automation-market-1158.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish MehraMarketsandMarkets INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biopreservation-media-storage-equipment-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/biopreservation.asp

View original content:http://www.prnewswire.com/news-releases/biopreservation-market-worth-4-9-billion-by-2025--exclusive-report-by-marketsandmarkets-301081801.html

SOURCE MarketsandMarkets

View original post here:
Biopreservation Market Worth $4.9 Billion by 2025 - Exclusive Report by MarketsandMarkets - Yahoo Finance

The study on the Cord Blood Banking Marketby Brand Essence Market Research is a compilation of systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also offers a precise analysis of the key challenges and growth prospects awaiting key players of the Cord Blood Banking market, including a concise summary of their corporate strategies and competitive setting.

In 2018, the Global Cord Blood Banking Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=12680&RequestType=Sample

Cord Blood Banking Market is valued at USD 1.24 Billion in 2018 and expected to reach USD 2.83 Billion by 2025 with the CAGR of 12.5 % over the forecast period.

A cord blood bank is a facility that stores umbilical cord blood for future use. Both private and public cord blood banks are developed in response to the reliable for cord blood in treating diseases of the blood and immune systems. Private or family cord blood banks are developed for autologous use or directed donation for a family member. Physicians recommend blood bank facility for a variety of reasons. Nowadays, Umbilical cord blood is used to treat many life-threatening diseases including leukemia, certain other cancers, and blood, immune and metabolic disorders. Over 30,000 transplants worldwide have been performed using stem cells from umbilical cord blood and because stem cell technologies continue to advance, the opportunities to utilize preserved cord blood and are steadily increasing. For example, Cryo-Cells umbilical cord blood banking service processes and cryogenically preserves these cells for potential therapeutic use.

Global cord blood banking market report is segmented on the basis of bank type, and regional & country level. Based upon bank type, cord blood banking market is classified as private, public, and hybrid. The regions covered in this Global Cord blood banking market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Cord blood banking market is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Cord blood banking Market Report

Global Cord Blood Banking Market Report covers prominent players are like Singapore Cord Blood Bank, CBR Systems, ViaCord LLC, Cordlife, FamiCord, Cryo-Save, Americord, Global Cord Blood Corporation, LifeCell and Jeevan Stem Cell Foundation and others.

Increasing Demand for Umbilical Cord Blood (UCB) Units for Regenerative Medicine Purposes is one of the Major Factors Drive the Market growth.

Increasing demand for umbilical cord blood (UCB) units for regenerative medicine purposes is expected to drive the growth of cord blood banking market. An increase in the number of UCB transplants specifies an expansion of utility in a broad spectrum of disease conditions. For example, the loaded umbilical cord blood in the stem cell can treat cancer, blood diseases like anemia, and some immune system disorders, which disrupt bodys ability to defend it. Apart from that, additional potential applications of UCB include hematopoietic transplantation, immunotherapy, and tissue engineering and regenerative medicine. In addition, increasing prevalence and incidence rate of chronic diseases is also supplementing the market growth. For example, According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. The increasing number of cancer patients is a major driver for the growth of stem cell/cord blood banking market. In 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States. However, stringent regulatory requirements may hamper the market growth. In spite of that, increasing technological developments in the field of cord blood storage and processing are also expected to provide an opportunity for the further growth of the market.

North America is Expected to Dominating the Global Cord Blood Banking Market.

North America market is anticipated to grow at a significant rate in the global cord blood banking market in upcoming years, mainly due to the growing demand for the umbilical cord blood in stem cell analysis in this region. In addition, well developed healthcare infrastructure and high adoption of advanced technology in healthcare in this region are also supplementing the market growth. The umbilical cord blood banking may be public and private. In North America, An estimated 4.0 million umbilical cord blood units have been saved for private or family use. In 2017, there are 28 public cord blood banks in North America. These banks have sufficient capacity for those demanding a donation of cord blood. The European cord blood banking market is a second largest market followed by Asia pacific.

By Bank Type:

By Regional & Country Analysis:

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Cord Blood Banking Market Size Growth Rate by Type (2014-2025)1.4.2 Topical Products1.4.3 Botulinum1.4.4 Dermal Fillers1.4.5 Chemical Peels1.4.6 Microabrasion Equipment1.4.7 Laser Surfacing Treatments1.5 Market by Application1.5.1 Global Cord Blood Banking Market Share by Application (2014-2025)1.5.2 Hospitals1.5.3 Dermatology Clinics1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Cord Blood Banking Market Size2.2 Cord Blood Banking Growth Trends by Regions2.2.1 Cord Blood Banking Market Size by Regions (2014-2025)2.2.2 Cord Blood Banking Market Share by Regions (2014-2019)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities

3 Market Share by Key Players3.1 Cord Blood Banking Market Size by Manufacturers3.1.1 Global Cord Blood Banking Revenue by Manufacturers (2014-2019)3.1.2 Global Cord Blood Banking Revenue Market Share by Manufacturers (2014-2019)3.1.3 Global Cord Blood Banking Market Concentration Ratio (CR5 and HHI)3.2 Cord Blood Banking Key Players Head office and Area Served3.3 Key Players Cord Blood Banking Product/Solution/Service3.4 Date of Enter into Cord Blood Banking Market3.5 Mergers & Acquisitions, Expansion Plans

Read More: https://industrystatsreport.com/Lifesciences-and-Healthcare/Cord-Blood-Banking-Market-Size-and-share/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Top Trending Reports:

https://brandessenceresearch.com/pharmaceutical/marine-pharmaceutical-market-industry

https://brandessenceresearch.com/agriculture/industrial-hemp-market-size

https://brandessenceresearch.com/healthcare/hematology-analyzer-and-reagent-market

https://brandessenceresearch.com/healthcare/esoteric-market-by-test

Read the original here:
Global Cord Blood Banking Market 2020 Production, Revenue, Average Product Price and Market Shares of Key Players 2025 - Jewish Life News

Wearing masks and other personal protective equipment (PPE) can slow the spread of Covid-19. The USCenters for Disease Control and Prevention recommends everyone wear some kind of face-covering in public places, especially where social distancing is difficult to maintain. And health workers are donning additional coverings, such as gowns. Yet all such protective gear shares one significant problem: people still risk becoming infected with the novel coronavirus if they accidentally touch areas of the fabric that are contaminated with viral particles. So researchers are working to develop cloth that could inactivate or repel coronavirusesideally including the one that causes Covid-19and other pathogens.

For latest updates and live news on coronavirus, click here

People can transfer infectious particles to their hands if they touch the front of a mask during use or when they remove gowns or other PPE, according to Chandan Sen, director of the Indiana Center for Regenerative Medicine and Engineering at Indiana University. He and his colleagues have been developing a way to render those particles and other infectious agents harmless. The team researches electroceutical materials that wirelessly generate electric fields across the surface of the fabric, Sen says. Those fields can disrupt the behaviour of bacteria or viruses on the cloth.

The beauty of this [technology] is the inherently simple design, he says. The polyester material is printed with alternating spots of silver and zinc resembling polka dots. They are one to two millimetres wide and spaced one millimetre apart. When the electroceutical material is dry, it functions as an ordinary fabric. But if it gets dampenedsay, with saliva, vapour from a coughed updropletsor other bodily fluidsions in the liquid trigger an electrochemical reaction. The silver and zinc then generate a weak electric field that zaps pathogens on the surface.

The researchers co-developed the material with the biotechnology company Vomaris Innovations in 2012. Last year, they showed that the technology could be used to treat bacterial biofilms in wounds. A clinical trial is underway to further evaluate the fabrics effectiveness as a Food and Drug Administrationcleared dressing for wound care, Sen says.

In response to the Covid-19 pandemic, Sens team tested its existing material on a different coronavirus strain that causes a respiratory illness in pigs and on an unrelated type of pathogen called a lentivirus. We wanted to know how broadly this principle could be applicable, he says. In a study posted on the preprint server ChemRxiv in May, Sens team reported that its electroceutical fabric destabilised both viruses, leaving them unable to infect cells. The researchers plan to submit the results to a peer-reviewed journal as well.

To study the fabrics action, they placed a liquid solution containing viral particles onto the electroceutical fabric and a polyester control fabric without the metal dots. After the droplets were fully absorbed, and the samples had rested for one to five minutes, the researchers recovered viral particles from both fabrics and tested whether they could still infect the types of cells they typically target.

The data presented here show that, of the total virus that was recovered, a significant percentage was inactivated, says Jeff Karp, a professor of medicine at Brigham and Womens Hospital in Boston and co-leader of an N95 respirator working group at the Massachusetts General Brigham Center for COVIDInnovation. Karp, who was not involved with the study, adds that the researchers did not test all of the virus that they had placed on the cloth. In fact, the majority of virus was not recovered from the textiles examined in this study, he says. Sen responds that his team focused on sampling only enough viral particles to show that the fabric had rendered them unable to infect cells. The researchers recovered roughly 44 percent of the particles from the electroceutical fabric samples that had rested for one minute. And they retrieved 24 percent of them from the samples that had rested for five minutes.

The materials virus-fighting abilities have not been tested specifically on SARS-CoV-2, the coronavirus that causes Covid-19. The researchers findings with the two viruses they studied, however, gave them hope that this could apply more widely, Sen says. He adds that large-scale manufacturing of the electroceutical fabric is already possible and that the costs of producing it are relatively low. The metal dots could be printed directly onto the front surfaces of masks, he suggests. Or an electroceutical fabric could be inserted between the front of a mask and the wearers face.

If a virus-stopping PPE material were widely available, it could limit the novel coronaviruss ability to spread. There is a huge unmet need to better understand modes of viral transfer that lead to virus transmission, Karp says. As we develop a better understanding of this, there is a huge immediate need to develop and quickly apply solutions that can reduce transmission.

Metal dots are not the only potential approach. Paul Leu, director of an advanced materials laboratory at the University of Pittsburgh, and his colleagues are developing a textile coating that repels bodily fluids, proteins and bacteria. It also repels one strain of adenovirus that causes respiratory illness and another that causes conjunctivitis, as reported in ACS Applied Materials & Interfaces in April. Leus team has also not tested the material with the novel coronavirus itself, however. The main thing with testing [the coating on] SARS-CoV-2 is the biosafety level you need to test it, because its very hazardous, he says. Still, his team plans to see how well textiles with this coating repel a different coronavirus.

Leu says the coating, which remains repellent even after ultrasonic washing and scraping with a razor blade, could make PPE safer for wearers to take off. It could also be used on hospital bed linens, drapes and waiting room chairs, the researchers note in the study. But Leu points out that the coating is intended for use with medical textiles that are already considered reusable. His team has not tested it on single-use masks or N95s, but he thinks it could potentially damage them. Still, he says, the coating could work well for cloth masks such as those now being worn by many among the general public.

By developing materials that kill or repel viruses, researchers hope to make masks and other protective gear safer to remove and more effective against all viruses. If the common person were to have PPE that wouldnt spread infection, Sen says, I think thats a big, big deal.

View original post here:
Electrified fabric could zap the coronavirus on masks, clothing - Deccan Herald

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Market Dynamics

Growth Drivers

Challenges

Market Trends

Companies Profiled

For more information about this report visit https://www.researchandmarkets.com/r/ufteqn

Read more from the original source:
Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire